Refine
Has Fulltext
- yes (32)
Is part of the Bibliography
- yes (32)
Document Type
- Journal article (23)
- Preprint (5)
- Conference Proceeding (4)
Language
- English (32)
Keywords
- PET (17)
- Positronen-Emissions-Tomografie (17)
- positron emission tomography (9)
- SPECT (5)
- neuroendocrine tumor (5)
- 18F-FDG (4)
- RADS (4)
- SSTR (4)
- 18F-DCFPyL (3)
- DaTscan (3)
- PET/CT (3)
- PSMA (3)
- Prostate Cancer (3)
- ageing (3)
- prostate cancer (3)
- somatostatin receptor (3)
- theranostics (3)
- vandetanib (3)
- 11C-HED (2)
- 18F-FDS (2)
- 18F-LMI1195 (2)
- Ioflupane (2)
- PRRT (2)
- PSMA-PET (2)
- PSMA-RADS (2)
- Parkinson (2)
- Parkinson Disease (2)
- Parkinson-Krankheit (2)
- Positron Emission Tomography (2)
- Stammzelle (2)
- TKI (2)
- Virchow Node (2)
- [177Lu]-DOTATATE/-DOTATOC (2)
- [68Ga] (2)
- cardiomyocytes (2)
- fatty acid (2)
- heart failure (2)
- hiPSC-CM (2)
- induced pluripotent stem cells (2)
- medullary thyroid carcinoma (2)
- molecular imaging (2)
- myocardial sympathetic innervation imaging (2)
- personalized medicine (2)
- personalized treatment (2)
- precision medicine (2)
- stem cell therapy (2)
- tracer (2)
- tumor heterogeneity (2)
- tyrosine kinase inhibitor (2)
- 11C-Hydroxyephedrine (1)
- 11C-hydroxyephedrine (1)
- 123I-Ioflupane (1)
- 123I-mIBG (1)
- 123I-metaiodobenzylguanidine (1)
- 18F-DCFPL (1)
- 18F-flurpiridaz (1)
- 18FFBnTP (1)
- 2- deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-18F-fluoro-D-sorbitol (1)
- 68Ga-DOTANOC (1)
- 68Ga-DOTATATE (1)
- 68Ga-DOTATATE/-TOC (1)
- 68Ga-DOTATOC (1)
- 99mTc-DTPA (1)
- AI (1)
- Antidepressants (1)
- Cardiovascular diseases (1)
- DCGAN (1)
- ECG (1)
- GAN (1)
- GI (1)
- Ganglia (1)
- Gastrointestinal (1)
- Glomerular filtration (1)
- HFmrEF (1)
- Heart failure (1)
- Imaging pitfalls (1)
- MDD (1)
- MI-RADS (1)
- MPI (1)
- MRI (1)
- Magnetresonanztomografie (1)
- Medullärer Schilddrüsenkrebs (1)
- Myokarditis (1)
- Neuroendocrine (1)
- Neuroendocrine Tumor (1)
- Nierenfunktionsstörung (1)
- Oncology (1)
- PROMISE (1)
- Pancreas (1)
- Parkinsonism (1)
- Parkinson’s disease (1)
- Pitfall (1)
- Positron-Emission Tomography (1)
- Positronenemissionstomografie (1)
- Prostata (1)
- Radionuclide Therapy (1)
- Radiotracer (1)
- SPECT/CT (1)
- SSTR-PET (1)
- SSTR-RADS (1)
- Single-Photon-Emissions-Computertomographie (1)
- Standardisierung (1)
- Tracer (1)
- ZDF rats (1)
- [68Ga]DOTATOC (1)
- \(^{18}\)F-FDG (1)
- \(^{18}\)F-fluorodeoxyglucose (1)
- antidepressant (1)
- artificial intelligence (1)
- cardiac neurohormonal system (1)
- cardiac sympathetic nerve system (1)
- cardiac sympathetic nervous system (1)
- coronary artery disease (1)
- depression (1)
- diabetes (1)
- diabetic cardiomyopathy (1)
- heart failure with mid-range ejection fraction (1)
- hydroxyephedrine (1)
- inflammation (1)
- interobserver (1)
- interreader (1)
- kidney (1)
- machine learning (1)
- magnetic resonance imaging (1)
- major depressive disorder (1)
- moycardial sympathetic innervation (1)
- myocardial perfusion imaging (1)
- myocarditis (1)
- neuroendocrine neoplasia (1)
- nuclear cardiology (1)
- pancreas (1)
- peptide receptor radionuclide therapy (1)
- phaeochromocytoma (1)
- prostate-specific membrane antigen (1)
- prostate-specific membrane antigen (PSMA) (1)
- quantification (1)
- radiotracer (1)
- renal failure (1)
- renal imaging (1)
- reporting and data system (1)
- reporting and data systems (1)
- single photon emission computed tomography: sympathetic nerve (1)
- somatostatin receptor (SSTR) (1)
- split renal function (1)
- standardization (1)
- standardized reporting (1)
- storage vesicle turnover (1)
- stroke (1)
- sympathetic nervous system (1)
- unilateral ureteral obstruction (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (32) (remove)
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (16)
- Johns Hopkins University School of Medicine (4)
- Department of Biomedical Imaging, National Cerebral and Cardiovascular Research Center, Suita, Japan (2)
- Division of Medical Technology and Science, Department of Medical Physics and Engineering, Course of Health Science, Osaka University Graduate School of Medicine, Suita Japan (2)
- Institut for Molecular Biology and CMBI, Department of Genomics, Stem Cell Biology and Regenerative Medicine, Leopold-Franzens-University Innsbruck, Innsbruck, Austria (2)
- Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD, USA (2)
- Department of Nuclear Medicine, Kanazawa University (1)
- Hospital Augsburg, Augsburg, Germany (1)
- Johns Hopkins School of Medicine, Baltimore, MD, U.S. (1)
- Johns Hopkins School of Medicine, Baltimore, MD, USA (1)
EU-Project number / Contract (GA) number
- 701983 (30)
Objective: Radiotracers targeting prostate-specific membrane antigen (PSMA) have increasingly been recognized as showing uptake in a number of normal structures, anatomic variants, and non-prostate-cancer pathologies. We aimed to explore the frequency and degree of uptake in peripheral ganglia in patients undergoing PET with the PSMA-targeted agent \(^{18}\)F-DCFPyL.
Methods: A total of 98 patients who underwent \(^{18}\)F-DCFPyL PET/CT imaging were retrospectively analyzed. This included 76 men with prostate cancer (PCa) and 22 patients with renal cell carcinoma (RCC; 13 men, 9 women). Scans were evaluated for uptake in the cervical, stellate, celiac, lumbar and sacral ganglia. Maximum standardized uptake value corrected to body weight (SUV\(_{max}\)), and maximum standardized uptake value corrected to lean body mass (SUL\(_{max}\)) were recorded for all ganglia with visible uptake above background. Ganglia-to-background ratios were calculated by dividing the SUV\(_{max}\) and SUL\(_{max}\) values by the mean uptake in the ascending aorta (Aortamean) and the right gluteus muscle (Gluteusmean).
Results: Overall, 95 of 98 (96.9%) patients demonstrated uptake in at least one of the evaluated peripheral ganglia. With regard to the PCa cohort, the most frequent sites of radiotracer accumulation were lumbar ganglia (55/76, 72.4%), followed by the cervical ganglia (51/76, 67.1%). Bilateral uptake was found in the majority of cases [lumbar 44/55 (80%) and cervical 30/51 (58.8%)]. Additionally, discernible radiotracer uptake was recorded in 50/76 (65.8%) of the analyzed stellate ganglia and in 45/76 (59.2%) of the celiac ganglia, whereas only 5/76 (6.6%) of the sacral ganglia demonstrated \(^{18}\)F-DCFPyL accumulation. Similar findings were observed for patients with RCC, with the most frequent locations of radiotracer uptake in both the lumbar (20/22, 90.9%) and cervical ganglia (19/ 22, 86.4%). No laterality preference was found in mean PSMA-ligand uptake for either the PCa or RCC cohorts.
Conclusion: As PSMA-targeted agents become more widely disseminated, the patterns of uptake in structures that are not directly relevant to patients’ cancers must be understood. This is the first systematic evaluation of the uptake of \(^{18}\)F-DCFPyL in ganglia demonstrating a general trend with a descending frequency of radiotracer accumulation in lumbar, cervical, stellate, celiac, and sacral ganglia. The underlying biology that leads to variability of PSMA-targeted radiotracers in peripheral ganglia is not currently understood, but may provide opportunities for future research.
Heart failure is one of the growing causes of death especially in developed countries due to longer life expectancy. Although many pharmacological and instrumental therapeutic approaches have been introduced for prevention and treatment of heart failure, there are still limitations and challenges. Nuclear cardiology has experienced rapid growth in the last few decades, in particular the application of single photon emission computed tomography (SPECT) and positron emission tomography (PET), which allow non-invasive functional assessment of cardiac condition including neurohormonal systems involved in heart failure; its application has dramatically improved the capacity for fundamental research and clinical diagnosis. In this article, we review the current status of applying radionuclide technology in non-invasive imaging of neurohormonal system in the heart, especially focusing on the tracers that are currently available. A short discussion about disadvantages and perspectives is also included.